Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study
VA Office of Research and Development
Summary
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.
Description
This project will quantify and compare the effects of a pharmacist-led telehealth-delivered intervention versus usual care on arthritis flare burden and serum urate goal achievement in 310 U.S. Veterans with gout enrolled from five VA medical centers. The project will quantify the effects of the intervention on patient-reported outcomes (improvements in health-related quality of life, pain interference, and participant global assessment).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * US Veterans over the age of 18 years with physician-diagnosed * Documented hyperuricemia (SU \>6.8 mg/dL) * Satisfy ACR/EULAR gout classification criteria * Report 1 or more flares in the prior 6 months * Receipt of a new ULT prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria Exclusion Criteria: * Any patient intolerant or unable to take ULTs (allopurinol or febuxostat) * Patients with a rheumatology encounter within the prior 3 months
Interventions
- OtherPharmacist-Led
Pharmacist will conduct regular telehealth visits with Veterans during dose escalation phase of gout treatment
Locations (5)
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha, Nebraska
- VA Portland Health Care System, Portland, ORPortland, Oregon
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, Pennsylvania
- VA Salt Lake City Health Care System, Salt Lake City, UTSalt Lake City, Utah
- VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, Washington